Avid Bioservices Inc (CDMO)

[geocappy1]

Absolutely KT. I also think there were many other avenues to go with Bavi even before the news about Gilead. As you say, hopefully, they followed the patients and have the followup data.

To the best of my knowledge all the other candidates other than Gilead involve using the drug in combination with the current SOC including INF. It would appear that with this result from Gilead that any one of the companies looking to get a leg up on the competition could have an interest in Bavi. Especially, the candidates like Gilead's that already can achieve the necessary reduction in viral activity but need only to find a way to hold it. Additional activity from Bavi would be a bonus.